Business Wire Feed
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization more...
New Peer-Reviewed Protocol Gives Critical Care Teams a Faster, Simpler Way to Guide Sepsis Fluid Decisions
Co-authored by Stanford’s Dr. Carolyn Kaufman and Flosonics Medical CMO Dr. Jon-Emile Kenny, the SaFER framework uses a wearable Doppler patch to help critical care teams determine whether IV fluids will help or harm a more...
Sensome Announces Successful Proof‑of‑Concept Adding Its Biological Intelligence to Robotic Thrombectomy
Sensome’s Clot‑Sensing Guidewire, Steered by Robocath’s Robotic Systems, Demonstrates Path Towards Physical AIPARIS--(BUSINESS WIRE)--#cardiology--Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced successful Proof of Concept (POC) cases using its Clotild® more...
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, following vaccination with 3 doses Data on certain HPV-related oropharyngeal cancers reinforce the importance of vaccination for both females and malesRAHWAY, more...
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients initiated atirmociclib within 3 more...
Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan
OXFORD, England & TOKYO--(BUSINESS WIRE)--#Nanopore--Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan’s leading genetic testing more...
Doximity Study Finds Physicians Rapidly Adopting AI, But Accuracy Concerns Persist
94% of physicians are using AI or interested, but 71% are concerned about its accuracy and reliabilitySAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released a new report more...
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and more...
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services’ more...
UnitedHealthcare Expands Doula Offering to Employer-Sponsored Plans Nationwide
More than 7.2 million members may have access to personalized support through eligible plans--(BUSINESS WIRE)--UnitedHealthcare today announced the national expansion of its doula offering, now available to people enrolled in eligible health plans through their more...
908 Devices to Present at the Sidoti Small Cap Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp more...
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis
Almirall announces positive, top-line results from Phase 3 ADorable-1 trial ADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) more...
L&T Technology Services Launches NVIDIA-Powered AI Lung Digital Twin Platform for Advanced Respiratory Diagnostics
Leveraging deep learning for immersive 3D visualization, integrated CT imaging workflows and enhanced precision in lung navigation and surgical planningSAN JOSE, Calif.--(BUSINESS WIRE)--$LTTS #3DVisualization--L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a global leader in more...
Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers
New findings show that Signatera status can help identify high-risk patients and inform non-operative management and surveillance strategiesAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced two more...
AHF Urges EU to Stop Blocking Health Equity
BRUSSELS--(BUSINESS WIRE)--#EUStopBlockingHealthEquity--AIDS Healthcare Foundation (AHF) Europe will hold an advocacy action in Brussels on March 18 at 11:00 a.m. CET on Archimedes Street, followed by an in-person and virtual press conference at Press Club Brussels more...
RevnaBio Secures Triple International Laboratory Accreditation to Expand Precision Medicine and Clinical Research Infrastructure in Africa
A2LA accreditation across ISO 15189, ISO 20387, and ISO/IEC 17043 strengthens diagnostic quality for patients while enabling global pharmaceutical and research partnerships.ACCRA, Ghana--(BUSINESS WIRE)--#A2LA--RevnaBio today announced that it has received triple accreditation from the American more...
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
KERENDIA® (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerular filtration rate (eGFR) slope from baseline to Month 32 – a surrogate endpoint for slowing kidney disease progression1 more...
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO’s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs more...
YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)
SHANGHAI--(BUSINESS WIRE)--YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for YOLT-202, the company’s more...
Advanced eClinical Training Expands Nationwide Clinical Partner Network, Strengthening Medical Assistant Workforce Pipeline
NEW YORK--(BUSINESS WIRE)--Advanced eClinical Training (ACT), a national healthcare workforce training provider, today announced the continued expansion of its nationwide clinical partner network, now spanning more than 1,000 healthcare sites across the United States. The more...
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) more...
ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery Centers
Agreement will expand access to next-generation technology for cardiac electrophysiology proceduresNEW YORK--(BUSINESS WIRE)--ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter more...
OpenFold Consortium Announces Major OpenFold3 Update and Public Release of Training Data for Reproducible Biomolecular AI
Publishes OpenFold3 training datasets via Amazon Web Service’s (AWS) Registry of Open Data, alongside model weights, training and inference code, and evaluation scripts, enabling independent reproduction, benchmarking, and retraining Updates benchmarks and evaluation tooling, showing more...
Jackson Healthcare President Shane Jackson Honored on “Staffing 100” List of Leaders Shaping the Workforce Solutions Industry
2026 Marks Jackson’s Ninth Consecutive Appearance on Staffing Industry Analysts’ ListATLANTA--(BUSINESS WIRE)--Jackson Healthcare®, the trusted authority in healthcare talent and workforce solutions, today announced that its president, Shane Jackson, has been recognized on the 2026 more...
Western Alliance Bank Launches Healthcare Industry Specialization, Led by Industry Veteran Jennifer Hwang
Specialized commercial and industrial banking team tailors solutions to companies across the healthcare sectorPHOENIX--(BUSINESS WIRE)--Western Alliance Bank (NYSE: WAL) today announced the launch of its specialized Healthcare commercial banking team, led by industry executive Jennifer more...